Mirae Asset Global Etfs Holdings Ltd. Larimar Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 13,016 shares of LRMR stock, worth $94,626. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,016Holding current value
$94,626% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
111Shares Held
68MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$154 Million3.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$43.9 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$31.8 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$31.5 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$28.1 Million11.62% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $315M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...